Hydrocodone IR is under clinical development by Elysium Therapeutics and currently in Phase I for Opium (Opioid) Addiction. According to GlobalData, Phase I drugs for Opium (Opioid) Addiction have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Hydrocodone IR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hydrocodone IR overview
Hydrocodone immediate release is under development for the treatment of prescription opioid use disorder and opium (Opioid) addiction. It acts by targeting mu-type opioid receptor. The drug candidate is developed based on O2P (oral overdose protection) technology. It is an immediate release formulation. It is administered through oral route.
Elysium Therapeutics overview
Elysium Therapeutics, a healthcare company that develops opioid pain relievers. The company is headquartered in United States.
For a complete picture of Hydrocodone IR’s drug-specific PTSR and LoA scores, buy the report here.